Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcium agonists in hyperparathyroidism.

Alberto Falchetti1

  • 1Department of Internal Medicine, University of Florence and Centro di Riferimento Regionale Tumori Endocrini Ereditari, Azienda Ospedaliera Careggi, Florence, Italy. a.falchetti@dmi.unifi.it

Expert Opinion on Investigational Drugs
|March 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocrine-related osteoporosis: the state of the art.

Frontiers in endocrinology·2026
Same author

Beyond the Genome: Can Epigenetics Forecast Therapeutic Success in Graves' Disease and Thyroid Eye Disease?

International journal of molecular sciences·2026
Same author

Micro-costing analysis from Italian Guidelines for the management of sporadic primary hyperparathyroidism.

Global & regional health technology assessment·2025
Same author

Phosphate metabolism in primary hyperparathyroidism: a real-life long-term study.

Endocrine·2025
Same author

Molecular Pathophysiology of Parathyroid Tumorigenesis-The Lesson from a Rare Disease: The "MEN1 Model".

International journal of molecular sciences·2024
Same author

Glycogen Storage Disease Type I and Bone: Clinical and Cellular Characterization.

Calcified tissue international·2024
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

New drugs targeting calcium-sensing receptors offer promising treatments for hyperparathyroidism (HPT) and associated hypercalcaemia, potentially reducing parathyroid hormone secretion and cell proliferation. Further research is needed for widespread clinical adoption.

Area of Science:

  • Endocrinology
  • Nephrology
  • Pharmacology

Background:

  • Primary hyperparathyroidism (PHPT) and uraemic hyperparathyroidism (HPT) are significant causes of hypercalcaemia.
  • Current treatments, including surgery and palliative medical therapies, have limitations.
  • There is a need for more effective therapeutic strategies for HPT-dependent hypercalcaemia.

Purpose of the Study:

  • To explore novel therapeutic approaches for hyperparathyroidism.
  • To evaluate new molecules targeting the calcium-sensing receptor for HPT management.

Main Methods:

  • Development of novel molecules targeting the specific membrane receptor for extracellular calcium.
  • Evaluation of these molecules' effects on parathyroid hormone secretion and parathyroid cell proliferation.

Related Experiment Videos

  • Analysis of preliminary clinical trial data for efficacy and safety.

    • Main Results:

    • New molecules effectively reduce parathyroid hormone secretion and parathyroid cell proliferation.
    • These drugs show potential in regulating bloodstream calcium levels in HPT patients.
    • Preliminary clinical trials indicate good efficacy and safety.

    Conclusions:

    • Novel therapies targeting the calcium-sensing receptor represent a promising advancement in HPT treatment.
    • These drugs may offer a more effective alternative to current palliative treatments.
    • Further extensive research, including in vitro, in vivo, and long-term clinical studies, is required before widespread clinical use.